Spots Global Cancer Trial Database for gefitinib
Every month we try and update this database with for gefitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases | NCT00238251 | Lung Cancer Metastatic Canc... | gefitinib temozolomide radiation thera... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer | NCT03170180 | Stomach Neoplas... | Sunitinib Gefitinib Imatinib | 20 Years - | Samsung Medical Center | |
| Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00033449 | Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... | gefitinib radiation thera... cisplatin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Blood Detection of EGFR Mutation For Iressa Treatment | NCT02282267 | Lung Adenocarci... | Gefitinib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00075439 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | NCT00042991 | Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | gefitinib radiation thera... pharmacological... laboratory biom... | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00014144 | Bladder Cancer Transitional Ce... Urethral Cancer | gefitinib | - | SWOG Cancer Research Network | |
| Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma | NCT00052754 | Sarcoma | gefitinib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC) | NCT00824746 | Carcinoma, Non-... | Gefitinib retre... | 18 Years - | Chonnam National University Hospital | |
| Open-Label Extension of Other SZ1839 (Iressa) Trials | NCT00635973 | Cancer | Gefitinib (Ires... | 18 Years - | AstraZeneca | |
| Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations | NCT00891579 | Non Small Cell ... | Pemetrexed (Ali... Gefitinib (IRES... | 18 Years - 80 Years | Chinese Society of Lung Cancer | |
| Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer | NCT00239304 | Head and Neck N... | Gefitinib Cisplatin Radiotherapy | 18 Years - | AstraZeneca | |
| Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients | NCT01749072 | Non-small Cell ... Effects of Chem... | Gefitinib group Vinorelbine, If... | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery | NCT00258297 | Esophageal Canc... | gefitinib conventional su... enzyme inhibito... neoadjuvant the... protein tyrosin... surgery | 18 Years - | University of Rochester | |
| ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | NCT00252798 | Non Small Cell ... | Gefitinib Carboplatin Paclitaxel Radiation | 18 Years - | AstraZeneca | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. | NCT03381066 | Completely Rese... | gefitinib, peme... Vinorelbine, ci... | 20 Years - | Yonsei University | |
| Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors | NCT00039390 | Unspecified Adu... | capecitabine gefitinib pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | NCT03292133 | Lung Cancer | EGF816 Gefitinib | 18 Years - | Massachusetts General Hospital | |
| Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma | NCT04642547 | Hepatocellular ... Molecular Targe... | Lenvatinib and ... | 18 Years - 75 Years | RenJi Hospital | |
| Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) | NCT01312337 | Nonsmall Cell L... | salvage iressa | 18 Years - | Samsung Medical Center | |
| Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | NCT02179671 | Locally Advance... | Gefitinib AZD9291 Selumetinib+Doc... Tremelimumab | 18 Years - 130 Years | AstraZeneca | |
| UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer | NCT01037998 | Non-Small-Cell ... | UFUR and Iressa | 18 Years - | Taipei Veterans General Hospital, Taiwan | |
| Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer | NCT00077025 | Breast Cancer | Gefitinib Anastrozole | 18 Years - | AstraZeneca | |
| Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma | NCT02929693 | Cancer | gefitinib Yiqi-yangyin-ji... placebo | 18 Years - | Shanghai University of Traditional Chinese Medicine | |
| A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa | NCT01000740 | Non-small Cell ... | EGFR Mutation T... Ki-67 protein e... | - | AstraZeneca | |
| A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | NCT04239833 | Non-Small Cell ... | SH-1028 tablets Placebo SH-1028... Gefitinib Placebo Gefitin... | 18 Years - | Nanjing Sanhome Pharmaceutical, Co., Ltd. | |
| A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | NCT03292133 | Lung Cancer | EGF816 Gefitinib | 18 Years - | Massachusetts General Hospital | |
| Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy | NCT00095836 | Head and Neck C... | Gefitinib | 18 Years - | Massachusetts General Hospital | |
| Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer | NCT00423397 | Non-melanomatou... | PEG-interferon ... gefitinib | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Iressa in Prostate Cancer Patients | NCT00265070 | Prostate Cancer | Gefitinib | 18 Years - | AstraZeneca | |
| Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance | NCT02930954 | Non-small-cell ... | Gefitinib pemetrexed or g... bevacizumab | 18 Years - 70 Years | Tongji University | |
| Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene | NCT00588445 | Lung Cancer Non-small Cell ... Bronchioloalveo... | Gefitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | NCT01833572 | Non-small-cell ... | Gefitinib | 18 Years - | Fudan University | |
| Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00014170 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | gefitinib pharmacological... laboratory biom... questionnaire a... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin | NCT00054691 | Skin Cancer | Iressa | 18 Years - | M.D. Anderson Cancer Center | |
| ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | NCT01774721 | Non-small Cell ... | Dacomitinib (PF... Gefitinib | 18 Years - 99 Years | Pfizer | |
| Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer | NCT00066378 | Breast Cancer | anastrozole gefitinib | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | NCT03599518 | Non Small Cell ... | DS-1205c Gefitinib | 20 Years - | Daiichi Sankyo | |
| Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer | NCT00077025 | Breast Cancer | Gefitinib Anastrozole | 18 Years - | AstraZeneca | |
| ZD 1839 in Treating Patients With Metastatic Kidney Cancer | NCT00012337 | Kidney Cancer | gefitinib | - | National Cancer Institute (NCI) | |
| Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer | NCT00086957 | Breast Cancer | trastuzumab docetaxel gefitinib | 18 Years - | City of Hope Medical Center | |
| Third-line Treatment of Gefitinib in NSCLC Patients | NCT01933347 | Non Small Cell ... | Gefitinib | 18 Years - | Guangdong Association of Clinical Trials | |
| Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma | NCT02929693 | Cancer | gefitinib Yiqi-yangyin-ji... placebo | 18 Years - | Shanghai University of Traditional Chinese Medicine | |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC | NCT02299765 | Non-small Cell ... EGFR Activating... | Gefitinib gemcitabine carboplatin | 18 Years - 75 Years | Sichuan University | |
| A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations | NCT02824458 | EGFR Tyrosine K... | Apatinib Gefitinib Placebo | 18 Years - 70 Years | Sun Yat-sen University | |
| Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery | NCT00493025 | Esophageal Canc... | cisplatin gefitinib paclitaxel adjuvant therap... radiation thera... | 18 Years - 80 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) | NCT02856893 | NSCLC | Osimertinib Gefitinib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC) | NCT00452244 | Lung Cancer | simvastatin gefitinib only | 18 Years - | National Cancer Center, Korea | |
| ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer | NCT00014183 | Kidney Cancer | gefitinib | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib | NCT01405846 | Lung Cancer Head and Neck C... | Gefitinib | 18 Years - 80 Years | Papworth Hospital NHS Foundation Trust | |
| Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients | NCT02040064 | Non Small Cell ... | Gefitinib Tremelimumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | NCT00252798 | Non Small Cell ... | Gefitinib Carboplatin Paclitaxel Radiation | 18 Years - | AstraZeneca | |
| Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma | NCT00228488 | Head and Neck C... | Gefitinib | 18 Years - | AstraZeneca | |
| Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer | NCT00955695 | Lung Cancer | erlotinib hydro... gefitinib questionnaire a... quality-of-life... whole-brain rad... | 18 Years - | National Cancer Institute (NCI) | |
| Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic | NCT00127829 | Tumors | Gefitinib | 18 Years - | AstraZeneca | |
| Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | NCT00062270 | Lung Cancer | cisplatin docetaxel gefitinib gemcitabine hyd... conventional su... neoadjuvant the... radiation thera... | 19 Years - 120 Years | University of Alabama at Birmingham | |
| Phase II Iressa + Irradiation Followed by Chemo in NSCLC | NCT00333294 | Non-Small Cell ... | Gefitinib Radiation thera... Cisplatin Vinorelbine | 18 Years - 75 Years | AstraZeneca | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | NCT05834348 | Non-Small Cell ... | lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib | 18 Years - 100 Years | Pfizer | |
| Gefitinib in Treating Patients With Malignant Mesothelioma | NCT00025207 | Advanced Malign... Epithelial Meso... Recurrent Malig... Sarcomatous Mes... | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer | NCT00052169 | Breast Neoplasm... | ZD1839 in combi... | 18 Years - | NSABP Foundation Inc | |
| GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial | NCT02319577 | Non Small Cell ... | oral vinorelbin... Gefitinib | 18 Years - | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00217698 | Lung Cancer | cisplatin gefitinib gemcitabine hyd... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00217698 | Lung Cancer | cisplatin gefitinib gemcitabine hyd... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Bone Metastasis on the Survival of Gefitinib Effective Patients | NCT03157310 | Overal Survival... | Gefitinib | 18 Years - 85 Years | Qilu Hospital of Shandong University | |
| Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations | NCT03529084 | Carcinoma, Non-... | EFG816 erlotinib or ge... | 18 Years - | Novartis | |
| A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone | NCT01544179 | Non-Small Cell ... | Gefitinib Placebo Pemetrexed Cisplatin | 18 Years - 130 Years | AstraZeneca | |
| Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) | NCT00770588 | Non-small Cell ... | Gefitinib Placebo | 18 Years - | AstraZeneca | |
| Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT00536107 | Carcinoma, Non-... | Gefitinib CT or MRI Docetaxel | 18 Years - | AstraZeneca | |
| Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery | NCT00493025 | Esophageal Canc... | cisplatin gefitinib paclitaxel adjuvant therap... radiation thera... | 18 Years - 80 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | NCT03849768 | Non Small Cell ... | HS-10296 Gefitinib | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer | NCT00093652 | Esophageal Canc... | gefitinib oxaliplatin conventional su... neoadjuvant the... radiation thera... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung | NCT01466660 | Lung Neoplasms | Afatinib gefitinib | 18 Years - 90 Years | Boehringer Ingelheim | |
| Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases) | NCT02338011 | Non-Small Cell ... Brain Metastase... EGFR Gene Mutat... | Gefitinib WBRT | 18 Years - | Shanghai Chest Hospital | |
| Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature | NCT00198380 | Pneumonic-type ... Lung Adenocarci... | Gefitinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse | NCT00016991 | Brain and Centr... | gefitinib | 18 Years - | Duke University | |
| A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | NCT04239833 | Non-Small Cell ... | SH-1028 tablets Placebo SH-1028... Gefitinib Placebo Gefitin... | 18 Years - | Nanjing Sanhome Pharmaceutical, Co., Ltd. | |
| Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers | NCT01502202 | Non Small Cell ... Adenocarcinoma | Gefitinib Placebo Pemetrexed plus... | 18 Years - | National Cancer Center, Korea |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
